Head to Head Contrast: Edgewise Therapeutics (NASDAQ:EWTX) vs. Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sarepta Therapeutics and Edgewise Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6	13	9	0	2.11
Edgewise Therapeutics	1	2	6	1	2.70

Sarepta Therapeutics presently has a consensus target price of $33.84, suggesting a potential upside of 94.48%. Edgewise Therapeutics has a consensus target price of $36.67, suggesting a potential upside of 20.73%. Given Sarepta Therapeutics’ higher probable upside, equities analysts clearly believe Sarepta Therapeutics is more favorable than Edgewise Therapeutics.

Profitability

This table compares Sarepta Therapeutics and Edgewise Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-11.25%	-4.85%	-1.78%
Edgewise Therapeutics	N/A	-30.88%	-29.42%

Volatility & Risk

Sarepta Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500.

Earnings and Valuation

This table compares Sarepta Therapeutics and Edgewise Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$1.90 billion	0.96	$235.24 million	($3.01)	-5.78
Edgewise Therapeutics	N/A	N/A	-$133.81 million	($1.58)	-19.22

Sarepta Therapeutics has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

86.7% of Sarepta Therapeutics shares are held by institutional investors. 7.6% of Sarepta Therapeutics shares are held by insiders. Comparatively, 23.2% of Edgewise Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Sarepta Therapeutics beats Edgewise Therapeutics on 9 of the 14 factors compared between the two stocks.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.